Jörn Schattenberg

Hepatologist with independent views.

[LiverAim @LiverAim]

💚#LIVERAIM joins EASL's #LoveYourLiver at #UEGWeek2026!

🩺 Free, non-invasive liver checks and liver health awareness.
📍 Fira Barcelona Gran Via, outside the North entrance
🤝 Bringing early detection closer to you!

#LIVERAIM #LoveYourLiver
@IHIEurope @my_ueg @EASLnews

[United European Gastroenterology @my_ueg]

Join the Top Abstract Prize Awardees' presentations today to discover the science shaping the future of GI:

🔹 Anouk Overdevest: https://t.co/j3F0pWGuLt
🔹 Arianna Andreozzi: https://t.co/RrqgHrZBQR
🔹 Dania El Abyad (DDM Summit awardee): https://t.co/7hJOXNxCHl

#UEGWeek

[Aline Charabaty, MD, FACG, AGAF @DCharabaty]

5-yr #PROFILE @my_ueg #UEGWeek

🏆Top-down & combo Rx for the win in #Crohns

🔺Top-down
✅> to accelerated step-up
✅5x less ✂️, 2.5 less B2/B3 & 🏥

🔺Combo Rx IFX+AZA
⬇️immunogenic & non-immunogenic LOR
⬆️Rx durability
#DrNuruNoor
@LancetGastroHep https://t.co/LOK3uZvU2y

[EASLnews @EASLnews]

The closing Plenary of Day 2 at #SLDSummit 2026 is focused on the next wave of therapeutic development in SLD.

Metabolic directed and liver directed treatment strategies are being examined in depth, reflecting the rapidly expanding pipeline of potential interventions. Fresh data on metabolic modulation in MASLD and type 2 diabetes are contributing to the evolving evidence base.

The discussion is also tackling a key question in cirrhosis care, whether treatment goals should prioritise fibrosis regression or tangible clinical outcomes. A forward thinking exchange is setting the tone as we head into the final day of the Summit.

@schattenbergJ

[United European Gastroenterology @my_ueg]

UEG Week in Berlin is bringing together the digestive health community for four days of cutting-edge science, education, and networking.

Register by August 28 to benefit from the regular registration fee: 🔗 https://t.co/vgj1c6vNPr

[Naim Alkhouri @AlkhouriNaim]

Kicking off the Global Think Tank on Steatotic Liver Disease #SLD in beautiful Barcelona. This is the “most interactive meeting” in hepatology. @schattenbergJ @scottisaacsmd @FattyLiverA @PerspectumGroup @Echosens @MadrigalPharma

[Jörn Schattenberg @schattenbergJ]

Did you know that #compensated #cirrhosis in MASH can be reversed from pharmacological treatment ⁉️

Shown at @EASLedu @EASLnews today in the General Session and Published online by @NoureddinMD

https://t.co/KJXoFdVFet

[LiverAim @LiverAim]

#LIVERAIM networking session is starting at track hub8!
Join us and learn from @schattenbergJ and @PoseElisa how #biomarkers of #liverfibrosis can reshapethe future of Hepatology
#livertwitter #EASLCongress
@IHIEurope @EASLedu @EASLnews @AleksanderKrag @JVLazarus @MajaThiele

[Scott Isaacs @scottisaacsmd]

Addressing the rising global burden of #MASLD from the payors' perspective. @JVLazarus @younossi @schattenbergJ @DrLoomba @AlinaAllenMD
https://t.co/Mh7Htj3Ubv

[JHEP Reports @JHEP_Reports]

🟪NEW Article in press❕

The Weight of Choices: Prioritizing Lifestyle Over GLP-1 Receptor Agonist Therapy in Managing #MASLD

🔓#OpenAccess at 👉https://t.co/eRUMD9UrDk

#LiverTwitter

[Jörn Schattenberg @schattenbergJ]

Prevention to maintain GI Health 👨‍⚕️

Join me in #Homburg 🇩🇪 in person or online 💻 tonight 🌚 @bvpraevention
@BurdaStiftung

❗️Patient information event ❗️ #empowerment @EuropeLiver @DGVSJuGa @my_ueg @EASLnews

https://t.co/xzB47lo5ub

[United European Gastroenterology @my_ueg]

Kicking off #UEGWeek 2026!

The work on the Scientific Programme for #UEGWeek 2026 is underway! Huge thanks to all SciComm members and new chairs, @schattenbergJ (SciComm) & @maura_corsetti (PGT), for their dedication. Two days of exciting collaboration, ideas and discussions!

[Jörn Schattenberg @schattenbergJ]

@my_ueg Thank you UEG office! 💪 group and energetic ⚡️ meeting - stay 📻 tuned for UEG week updates

[EASLnews @EASLnews]

The approval of new drugs for SLD will significantly impact the field, driving a shift towards a more proactive approach to liver health. While challenges remain in terms of healthcare systems and reimbursement, the availability of effective treatments offers a crucial opportunity to improve patient outcomes and address the growing burden. @schattenbergJ #SLDSummit

[Jeffrey V. Lazarus @JVLazarus]

@EASLnews @AleksanderKrag @FrancqueSven @apdpdiabetes @brennap9 @MajaThiele @schattenbergJ @AlkhouriNaim @marurinella @FattyLiverA @fprusso73 @ajay_duseja @ArunJSanyalVCU @HannesHagstrom @rabataller @PoseElisa @LuisAntonioDiaz @BrettEFortuneMD @AlinaAllenMD @IsraelsenMads @tomhemmingk @NoureddinMD @melina_manolas @mromerogomez @DrJavierCrespo @FDA @JSGracia @juanpabloarab @Dr_Ampuero @pericas_jm @AASLDtweets @AmerGastroAssn @lucavalenti75 @SagiZelber @EuropeLiver @scottisaacsmd Dr @schattenbergJ presenting at the #SLDsummit on drug approvals Europe and the importance of diet and physical activity. Thank you for showing our article on social nutrition:
https://t.co/Ig3gFtzO6u

[EASLnews @EASLnews]

👇

[EASLnews @EASLnews]

⭐️We are proud to announce that Prof. Dr. Jörn Schattenberg, Director of the Department of Internal Medicine II at Saarland University Hospital, has been elected Chairman of the Scientific Committee of the United European Gastroenterology @my_ueg for the term 2026 - 2029! 👏

Dr. Schattenberg, whom EASL proudly nominated for this position, also serves on our EASL Policy, Public Health and Advocacy Committee, contributing his expertise to guide the Association’s policy and public affairs efforts.

Congratulations, @schattenbergJ , on this well-deserved recognition! 🎉

[Economist Enterprise @econ_enterprise]

Learn how through joint efforts, policy makers can take steps to help prevent, diagnose and treat #liverdisease, reducing the extensive health and economic impacts https://t.co/h9dSmF9TfQ

Supported by @ISGLOBALorg

[Jörn Schattenberg @schattenbergJ]

#Nutrition and #weight loss from medical therapy 💉 🔥 topic ❓role of surgery @my_ueg @SagiZelber @HannesHagstrom with 🔝 faculty #VerneaKeller @Saar_Uni #mary-elizabethPatti @JoslinDiabetes and #RubenNougeiras
🙌 ➡️ individualisation is 🗝️

[Naim Alkhouri @AlkhouriNaim]

@AngeloArmandi presenting on the 🔥 topic of MetALD! This condition affects 2-4% of the adult population in the US. Worse prognosis than MASLD, increasing cause for liver transplant! How to design MetALD trials?? @juanpabloarab @ebtapper @NoureddinMD @novonordisk